It’s vital that health care providers seek more efficient ways of managing resource intensive patients with wounds.1
The MolecuLight i:XTM Wound Intelligence Device offers maximum insights to facilitate evidence-based clinician decision making.2
Up to 9x faster healing
Incorporating the MolecuLight i:X wound assesment tool into standard care helps clinicians identify and treat fluorescent bacteria which has been shown to reduce the average closure time of chronic wounds from 200 to 22 days (up to 9x improvement over standard care).3
89% overall reduction in costs compared to the standard of care4
Integrating the MolecuLight i:X into routine wound care facilitates evidence-based clinician decision making and has been shown to reduce the cost of treating chronic wounds by 89% (compared to the standard of care). This has been shown to lead to:
More positive outcomes: Accelerates wound closure time which could lead to reduced visits3
More effective sampling: Visualises the location and distribution of bacterial load across the wound bed and periphery resulting in 54% more accurate swabbing4
More savings: Facilitates more responsible decision making on dressings, antimicrobials and antibiotics at the point of care5,6
Less ineffective wound treatments: Instead, informed dressing selection and objective feedback to track efficacy1,6
Less unnecessary drug use: Instead, optimizes therapies and supports responsible antimicrobial stewardship5,6
May accelerate wound closure3
Accurate wound assessment leads to more appropriate wound treatment which may accelerate wound closure.
MolecuLight i:X guided treatment increased the rate of wound healing (statistically significant) compared with the standard of care.3
Testimonials
“This wound would never have healed so quickly without the MolecuLight i:X and the gained insight to debride more frequently.”
Dr Stephan Landis, MD, FRCP(C) Guelph General Hospital, Guelph, Canada
“The MolecuLight i:X images show no red fluorescence on the gauze or wound and clinical signs and symptoms suggest nice wound healing. I will discontinue use of antimicrobial ointment and dressings and continue negative pressure wound therapy with regular gauze.”
Rose Raizman, RN-EC, MSc, Scarborough & Rouge Hospital, Toronto, Canada
“I would not have suspected high levels of Pseudomonas on this wound. Both the Infectious Disease physician and myself were surprised when seeing the MolecuLight i:X images, which influenced my dressing selection.”
Rosemary Hill, BSN, CWOCN, CETN(C) Vancouver Coastal Health, North Vancouver, Canada
REFERENCES
1. Lindholm C and Searle R. Wound management for the 21st century: combining effectiveness and effi ciency. Int Wound J. 2016 Jul;13 Suppl 2:5-15.
2. Wu YC et al. Handheld fl uorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. Int Wound J. 2016 Aug;13(4):449-53.
3. DaCosta RS et al. Point-of-care autofl uorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: fi rst-in-human results. PLoS One. 2015 Mar 19;10(3).
4. Ottolino-Perry K et al. Improved detection of wound bacteria using fl uorescence image guided wound sampling in diabetic foot ulcers. Int Wound J. 2017 Feb 28. doi: 10.1111/iwj.12717.
5. Hill R and Douglas JJ. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Proceedings of the Annual Symposium on Advanced Wound Care (SAWC); 2017 Apr 5-9; San Diego, CA. (Accepted).
6. Landis SL et al. Use of fluorescence imaging in visualizing bacteria in chronic ulcers and traumatic soft tissue damage. Proceedings of the Annual Meeting of the Society of Federal Health Professionals (AMSUS); 2016 Nov 29-Dec 2; National Harbor, MD.